NEUREN PHARMACEUT. ORDINARY (NEU) Short Interest
NEUREN PHARMACEUT. ORDINARY (ASX:NEU) had 4.86% of shares reported as short positions as of 16 July 2026, representing 6,166,187 shares. NEUREN PHARMACEUT. ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biopharmaceutical company focused on developing therapies for neurological conditions. The company is positioned in the biotechnology sector, leveraging its expertise in neuroscience to address unmet medical needs. Neuren's unique value lies in its targeted approach to treating rare neurological disorders, with a strong pipeline of innovative products.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4NEU intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Neuren Pharmaceuticals
Latest NEU news
All news- Neuren Pharmaceuticals (ASX:NEU) Draws Investor Attention After Recent Decline - Kalkine
googlenews
- Neuren Pharmaceuticals (ASX:NEU) US$35m EU trigger puts royalties back in focus - Stocks Down Under
googlenews
- Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens
kalkine
- ASX 200 Set for Monday Focus: Will Neuren (ASX:NEU) and Gold Stocks Lead the Market?
kalkine
- DAYBU recommended for approval in the European Union
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss NEU
Start a research thread or post the first pulse update